Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.80 |
| ▸ | RAB9A | P51151 | 5/20 | 0.80 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.80 |
| ▸ | PKM | P14618 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CBFB | Q13951 | 12/20 | 0.62 |
| ▸ | METAP2 | P50579 | 8/20 | 0.62 |
| ▸ | METAP1 | P53582 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20659617 | 0.99 | NPC1 (0.78) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL4805851 | 0.92 | NPC1 (0.69) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL10351275 | 0.89 | NPC1 (1.00) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL124377 | 0.86 | CBFB (0.81) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL179158 | 0.86 | CBFB (0.65) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL4813791 | 0.85 | NPC1 (0.58) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL125117 | 0.85 | CBFB (0.81) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL179155 | 0.83 | CBFB (0.63) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL125825 | 0.83 | CBFB (0.81) | NPC1RAB9ARUNX1PKMSMN1; SMN2 | |
| SCHEMBL179143 | 0.83 | CBFB (0.81) | NPC1RAB9ARUNX1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931352-B2 | Combination therapies for treating cancer | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3670509-B1 | INHIBITORS OF INV(16) LEUKEMIA | UNIV VIRGINIA PATENT FOUNDATION (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| EP-4085919-A2 | COMPOSITIONS AND METHODS TO TREAT CANCER | Novartis AG (CH) | 2022-11-09 | — | — | EP | disclosed |
| EP-3490557-B1 | COMBINATION THERAPIES FOR TREATING CANCER | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-11241421-B2 | Combination therapies for treating cancer | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| WO-2016025744-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132684-A9 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010132684-A2 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-0120396-B1 | TEST STRIP FOR THE DETECTION OF LEUCOCYTES IN URINE | MACHEREY-NAGEL & Co, Chemikalienhandel (DE) | 1990-05-30 | — | — | EP | disclosed |
| EP-0120396-A2 | Test strip for the detection of leucocytes in urine | MACHEREY-NAGEL & Co, Chemikalienhandel (DE) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | NPC1 1794/4885RAB9A 4300/4885RUNX1 10/4885 |
| US-11530413-B2 | Compositions and methods to treat cancer | TP53, BRCA1, NTPCR | NPC1 899/4885RAB9A 1418/4885RUNX1 2583/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | NPC1 1798/4885RAB9A 4308/4885RUNX1 10/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | NPC1 3011/4885RAB9A 1272/4885RUNX1 1/4885 |
| US-11931352-B2 | Combination therapies for treating cancer | BRD4, BET1, FLI1 | NPC1 2308/4885RAB9A 3425/4885RUNX1 36/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | NPC1 579/4885RAB9A 2581/4885RUNX1 183/4885 |
| US-11241421-B2 | Combination therapies for treating cancer | MCL1, MLLT1, FLI1 | NPC1 1895/4885RAB9A 3050/4885RUNX1 17/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | NPC1 1798/4885RAB9A 4308/4885RUNX1 10/4885 |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | RUNX1, CBFB, IKZF1 | NPC1 938/4885RAB9A 2235/4885RUNX1 1/4885 |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | RUNX1, CBFB, IKZF1 | NPC1 1074/4885RAB9A 2276/4885RUNX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.